Erhalten Sie eine woechentliche Zusammenfassung der neuesten psychedelischen Forschung, neuer Studien und Plattform-Updates direkt in Ihren Posteingang.
Kein Spam, nie. Jederzeit abbestellbar.
Die Geschichte der Psychedelika-Forschung — von der Entdeckung bis zu modernen klinischen Studien
Schlüsselereignisse
42
Substanzen
5
Jahrzehnte
10
Zeitspanne
1938 — 2025
42 Ereignisse
Die Prohibitionsära
1970–1990: Forschung weltweit eingestellt
LSD-25 first created at Sandoz Laboratories in Basel, Switzerland, during research on ergot alkaloids.
LSDApril 19: Hofmann accidentally discovers LSD's psychoactive effects, then self-experiments with 250µg.
LSDStoll reports on LSD's psychological effects in the Swiss Archives of Neurology and Psychiatry.
LSDPioneering studies on LSD for treating alcoholism at Weyburn Mental Hospital, Canada.
LSDCovert program exploring LSD and other substances for mind control; later widely condemned.
LSDBanker and amateur mycologist participates in a velada led by María Sabina.
PsilocybinThe article introduces psilocybin mushrooms to mainstream Western culture.
PsilocybinAlbert Hofmann at Sandoz identifies and synthesizes psilocybin and psilocin.
PsilocybinLeary and Richard Alpert begin systematic psilocybin research at Harvard University.
PsilocybinWalter Pahnke's double-blind study shows psilocybin reliably produces mystical experiences.
PsilocybinControversy over methodology and personal use leads to their departure.
PsilocybinGrowing concerns about recreational use lead Sandoz to halt LSD distribution to researchers.
LSDCalifornia becomes the first US state to ban LSD possession and sale.
LSDStaggers-Dodd Bill makes LSD possession a federal crime.
LSDNixon signs the CSA; LSD, psilocybin, mescaline, and DMT classified as Schedule I.
International treaty restricts psychedelics globally; beginning of worldwide prohibition.
Shulgin introduces MDMA to psychotherapy circles after publishing its synthesis.
MDMALeo Zeff begins using MDMA therapeutically, eventually introducing it to over 4,000 patients.
MDMADespite protests from therapists, MDMA placed in Schedule I via emergency scheduling.
MDMAMultidisciplinary Association for Psychedelic Studies established to support psychedelic research.
MDMAUniversity of New Mexico study marks the return of sanctioned psychedelic research in the US.
DMTPhenethylamines I Have Known And Loved catalogs 179 phenethylamine compounds.
MDMATryptamines I Have Known And Loved documents 55 tryptamine compounds.
DMTFranz Vollenweider at University of Zürich uses PET imaging to map psilocybin's brain effects.
PsilocybinYale study demonstrates rapid antidepressant effects of sub-anesthetic ketamine.
KetamineLaunch of the landmark psilocybin program that would reshape the field.
PsilocybinGriffiths et al. publish landmark paper showing psilocybin occasioned mystical-type experiences with lasting positive effects.
PsilocybinFirst modern RCT of MDMA-assisted psychotherapy shows 83% response rate for PTSD.
MDMAfMRI studies reveal psilocybin decreases default mode network activity.
PsilocybinFirst controlled LSD study in 40 years shows significant anxiety reduction in terminal patients.
LSDTwo landmark studies show psilocybin produces rapid, sustained antidepressant effects.
PsilocybinCOMPASS Pathways receives Breakthrough Therapy designation for psilocybin in treatment-resistant depression.
PsilocybinMAPS receives FDA Breakthrough Therapy designation, accelerating the path to approval.
MDMAFirst psychedelic-related compound approved by FDA; nasal spray for treatment-resistant depression.
KetamineFirst US state to create a legal framework for psilocybin-assisted therapy.
PsilocybinNature Medicine: 67% of participants no longer met PTSD criteria after 3 sessions.
MDMAFirst federal grant in 50 years for psychedelic research, studying psilocybin for tobacco cessation.
PsilocybinTGA reclassifies MDMA (for PTSD) and psilocybin (for depression) for supervised medical use.
FDA issues Complete Response Letter citing concerns about trial design and functional unblinding.
MDMALicensed service centers open, marking the first legal psilocybin therapy in the US.
PsilocybinSwitzerland broadens access to LSD and psilocybin under supervised medical programs.
Pivotal Phase III trial data for psilocybin in treatment-resistant depression announced.
Psilocybin